As At & T (T) Valuation Declined, Community Trust & Investment Co Upped Holding by $474,006; Bvf Upped Regulus Therapeutics (RGLS) Position by $9.67 Million as Stock Price Rose

January 19, 2018 - By Ellis Scott

Community Trust & Investment Co increased its stake in At & T Inc (T) by 2.24% based on its latest 2017Q3 regulatory filing with the SEC. Community Trust & Investment Co bought 12,154 shares as the company’s stock declined 7.81% while stock markets rallied. The institutional investor held 553,915 shares of the telecommunications equipment company at the end of 2017Q3, valued at $21.70M, up from 541,761 at the end of the previous reported quarter. Community Trust & Investment Co who had been investing in At & T Inc for a number of months, seems to be bullish on the $228.10 billion market cap company. The stock increased 0.01% or $0.005 during the last trading session, reaching $37.155. About 18.00 million shares traded. AT&T Inc. (NYSE:T) has declined 0.52% since January 19, 2017 and is downtrending. It has underperformed by 17.22% the S&P500.

Bvf Inc increased its stake in Regulus Therapeutics Inc (RGLS) by 294.93% based on its latest 2017Q3 regulatory filing with the SEC. Bvf Inc bought 9.67 million shares as the company’s stock rose 26.09% with the market. The hedge fund held 12.95M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $16.19M, up from 3.28 million at the end of the previous reported quarter. Bvf Inc who had been investing in Regulus Therapeutics Inc for a number of months, seems to be bullish on the $144.28M market cap company. The stock decreased 0.15% or $0.0021 during the last trading session, reaching $1.3879. About 678,295 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 73.20% since January 19, 2017 and is downtrending. It has underperformed by 89.90% the S&P500.

Among 7 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Regulus Therapeutics had 27 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Wednesday, November 2 by Needham. Needham maintained the shares of RGLS in report on Tuesday, June 28 with “Buy” rating. The rating was maintained by Needham with “Hold” on Wednesday, August 2. The rating was maintained by Chardan Capital Markets on Wednesday, December 7 with “Buy”. Wells Fargo initiated Regulus Therapeutics Inc. (NASDAQ:RGLS) on Friday, December 4 with “Outperform” rating. BMO Capital Markets maintained the shares of RGLS in report on Monday, June 12 with “Hold” rating. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Monday, December 11 by Wedbush. On Wednesday, December 20 the stock rating was maintained by Wedbush with “Buy”. As per Wednesday, August 2, the company rating was maintained by BMO Capital Markets. Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Wednesday, March 29. Wedbush has “Outperform” rating and $6 target.

Bvf Inc, which manages about $999.89 million and $786.73 million US Long portfolio, decreased its stake in Anaptysbio Inc by 280,066 shares to 1.38 million shares, valued at $48.20M in 2017Q3, according to the filing. It also reduced its holding in Loxo Oncology Inc (NASDAQ:LOXO) by 225,000 shares in the quarter, leaving it with 238,386 shares, and cut its stake in Chemocentryx Inc (NASDAQ:CCXI).

Investors sentiment increased to 1.35 in Q3 2017. Its up 0.74, from 0.61 in 2017Q2. It increased, as 9 investors sold RGLS shares while 11 reduced holdings. 11 funds opened positions while 16 raised stakes. 58.85 million shares or 159.76% more from 22.65 million shares in 2017Q2 were reported. Morgan Stanley accumulated 5,699 shares. Sweden-based Rhenman Asset Mngmt Ab has invested 0.09% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Element Capital Limited Liability reported 60,473 shares stake. California Public Employees Retirement Sys holds 177,600 shares or 0% of its portfolio. 11,500 were accumulated by Dowling And Yahnke Ltd Co. Hightower Advsr stated it has 20,248 shares or 0% of all its holdings. Bancshares Of Ny Mellon reported 34,189 shares stake. Northern Trust has 187,492 shares for 0% of their portfolio. Broadfin Cap Limited Liability Corp owns 4.29M shares or 0.79% of their US portfolio. Savings Bank Of America De stated it has 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Art Advsrs Lc holds 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 24,850 shares. Millennium Lc, New York-based fund reported 397,728 shares. Bvf Il reported 2.06% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). Barclays Public Limited Co owns 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 89 shares. Brookstone Cap Mgmt invested in 13,200 shares or 0% of the stock.

Among 29 analysts covering AT&T Inc. (NYSE:T), 10 have Buy rating, 1 Sell and 18 Hold. Therefore 34% are positive. AT&T Inc. had 68 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Thursday, January 26 by RBC Capital Markets. Wells Fargo maintained the stock with “Outperform” rating in Wednesday, April 12 report. As per Monday, July 27, the company rating was reinitiated by Goldman Sachs. The stock of AT&T Inc. (NYSE:T) has “Buy” rating given on Tuesday, June 28 by Deutsche Bank. FBR Capital maintained the stock with “Mkt Perform” rating in Thursday, January 26 report. As per Tuesday, July 19, the company rating was maintained by Citigroup. The firm has “Overweight” rating by Barclays Capital given on Monday, April 18. The firm has “Buy” rating given on Monday, March 14 by Citigroup. UBS downgraded AT&T Inc. (NYSE:T) on Wednesday, September 28 to “Neutral” rating. The company was maintained on Friday, July 15 by Barclays Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts